Literature DB >> 8128396

Antibiotic penetration into lung tissues.

D Honeybourne.   

Abstract

Mesh：

Substances：

Year:  1994        PMID： 8128396      PMCID： PMC474317          DOI： 10.1136/thx.49.2.104

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  54 in total

1.  In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent.

Authors:  M A Cooper; J M Andrews; J P Ashby; R S Matthews; R Wise
Journal:  J Antimicrob Chemother       Date:  1990-11       Impact factor: 5.790

Review 2.  Pharmacokinetics of antibiotics in cystic fibrosis patients with particular reference to the bronchopulmonary tree (review).

Authors:  E Bergogne-Berezin
Journal:  Infection       Date:  1987 Jul-Aug       Impact factor: 3.553

3.  Pulmonary deposition of nebulised pentamidine isethionate: effect of nebuliser type, dose, and volume of fill.

Authors:  M O'Doherty; S Thomas; C Page; C Bradbeer; T Nunan; N Bateman
Journal:  Thorax       Date:  1990-06       Impact factor: 9.139

4.  The use of combinations of trimethoprim and sulphonamides in the treatment of chest infections.

Authors:  D T Hughes
Journal:  J Antimicrob Chemother       Date:  1983-11       Impact factor: 5.790

5.  Uptake of antibiotics by human alveolar macrophages.

Authors:  W L Hand; R W Corwin; T H Steinberg; G D Grossman
Journal:  Am Rev Respir Dis       Date:  1984-06

6.  Relationship of high tissue concentrations of azithromycin to bactericidal activity and efficacy in vivo.

Authors:  J A Retsema; A E Girard; D Girard; W B Milisen
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

7.  Membrane transport of clindamycin in alveolar macrophages.

Authors:  W L Hand; N L King-Thompson
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

8.  Metabolism and disposition of clarithromycin in man.

Authors:  J L Ferrero; B A Bopp; K C Marsh; S C Quigley; M J Johnson; D J Anderson; J E Lamm; K G Tolman; S W Sanders; J H Cavanaugh
Journal:  Drug Metab Dispos       Date:  1990 Jul-Aug       Impact factor: 3.922

9.  Azithromycin concentrations at the sites of pulmonary infection.

Authors:  D R Baldwin; R Wise; J M Andrews; J P Ashby; D Honeybourne
Journal:  Eur Respir J       Date:  1990-09       Impact factor: 16.671

Review 10.  Pulmonary metabolism of foreign compounds: its role in metabolic activation.

Authors:  G M Cohen
Journal:  Environ Health Perspect       Date:  1990-04       Impact factor: 9.031
View more
  18 in total

Review 1.  Use of newer quinolones for the treatment of intraabdominal infections: focus on clinafloxacin.

Authors:  C E Nord
Journal:  Infection       Date:  1999 May-Jun       Impact factor: 3.553

2.  A physiologically based pharmacokinetic model for capreomycin.

Authors:  B Reisfeld; C P Metzler; M A Lyons; A N Mayeno; E J Brooks; M A Degroote
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

3.  Distribution and function of the peptide transporter PEPT2 in normal and cystic fibrosis human lung.

Authors:  D A Groneberg; P R Eynott; F Döring; Q Thai Dinh; T Oates; P J Barnes; K F Chung; H Daniel; A Fischer
Journal:  Thorax       Date:  2002-01       Impact factor: 9.139

4.  A Macrophage Infection Model to Predict Drug Efficacy Against Mycobacterium Tuberculosis.

Authors:  Kaitlyn Schaaf; Virginia Hayley; Alexander Speer; Frank Wolschendorf; Michael Niederweis; Olaf Kutsch; Jim Sun
Journal:  Assay Drug Dev Technol       Date:  2016-06-21       Impact factor: 1.738

5.  Aerosol phage therapy efficacy in Burkholderia cepacia complex respiratory infections.

Authors:  Diana D Semler; Amanda D Goudie; Warren H Finlay; Jonathan J Dennis
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

6.  An isoniazid analogue promotes Mycobacterium tuberculosis-nanoparticle interactions and enhances bacterial killing by macrophages.

Authors:  Tatiany J de Faria; Mariane Roman; Nicole M de Souza; Rodrigo De Vecchi; João Vitor de Assis; Ana Lúcia Gomes dos Santos; Ivan H Bechtold; Nathalie Winter; Maurilio José Soares; Luciano Paulino Silva; Mauro V De Almeida; André Báfica
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

7.  Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women.

Authors:  Kevin P Connors; Seth T Housman; J Samuel Pope; John Russomanno; Edward Salerno; Eric Shore; Susan Redican; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

8.  Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults.

Authors:  Coleman Rotstein; Gerald Evans; Abraham Born; Ronald Grossman; R Bruce Light; Sheldon Magder; Barrie McTaggart; Karl Weiss; George G Zhanel
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-01       Impact factor: 2.471

9.  Comparison of oral, nebulized and combination antibiotic treatment of Bordetella bronchiseptica in baboons (Papio spp.).

Authors:  Elizabeth A Clemmons; Deborah Chavez; Laura Condel; John W Dutton; Sharon Price; Robert Lanford
Journal:  J Vet Pharmacol Ther       Date:  2021-05-08       Impact factor: 1.567

Review 10.  Nebulized antibiotics for ventilator-associated pneumonia: a systematic review and meta-analysis.

Authors:  Fernando G Zampieri; Antonio P Nassar; Dimitri Gusmao-Flores; Leandro U Taniguchi; Antoni Torres; Otavio T Ranzani
Journal:  Crit Care       Date:  2015-04-07       Impact factor: 9.097
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.